Multisite gynecologic endometrioid adenocarcinomas: Can mutation profiling be used to distinguish synchronous primary cancers from metastases?

Dominique Barnes; Nissreen Mohammad; Lien Hoang; Michael Anglesio; Robert L Hollis; Charlie Gourley; Heather C Stuart; Mark S Carey; Gavin C E Stuart

doi:10.1016/j.gore.2022.101076

Multisite gynecologic endometrioid adenocarcinomas: Can mutation profiling be used to distinguish synchronous primary cancers from metastases?

Gynecol Oncol Rep. 2022 Oct 14:44:101076. doi: 10.1016/j.gore.2022.101076. eCollection 2022 Dec.

Authors

Dominique Barnes¹, Nissreen Mohammad², Lien Hoang², Michael Anglesio¹, Robert L Hollis³, Charlie Gourley³, Heather C Stuart⁴, Mark S Carey¹, Gavin C E Stuart¹

Affiliations

¹ Department of Obstetrics and Gynecology, University of British Columbia, Canada.
² Department of Pathology, Vancouver General Hospital and the University of British Columbia, Canada.
³ The Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, MRC Institute of Genetics and Cancer, University of Edinburgh, UK.
⁴ Department of Surgery, Vancouver General Hospital, and the University of British Columbia, Canada.

Abstract

It is well recognized that some patients with endometrioid gynecological cancers have tumors arising in multiple sites (ovary, endometrium, and endometriosis) at the time of diagnosis. Molecular analysis has helped discern whether these multisite cancers represent synchronous primary tumors or alternatively metastatic disease. We present a complex case of a patient with endometrioid carcinomas arising in multiple sites. We discuss the use of mutation profiling to discern clonality and highlight how this information may inform the clinical management of such cases.

Keywords: Clonality; Endometrioid carcinoma; Gynecologic cancers; Mutation analysis.

Publication types

Case Reports